Author

Andrea Lo‐Rossi

Observed name: Andrea Lo-Rossi

Institution: Genentech

Observed institution: Genentech

ORCID: 0009-0001-6745-810X

Observed ORCID: 0009-0001-6745-810X

OpenAlex ID: A5115022856

Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐ GemOx : A Multicenter Cohort Study

2025 · Samuel Yamshon, Jean L. Koff, et al. · American Journal of Hematology · 12

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study

2024 · Samuel Yamshon, Jean L. Koff, et al. · Blood · 1

Treatment patterns and outcomes for second-line therapy in large B-cell lymphoma: results from the LEO CReWE study

2026 · Jean L. Koff, Melissa C. Larson, et al. · Blood Cancer Journal

Ee461 the Total Cost of Care and Budget Impact of Introducing Mosunetuzumab Plus Polatuzumab Vedotin for Second-line or Later (2l+) Treatment of Relapsed/refractory Large B-cell Lymphoma (lbcl) to a United States (us) Health Plan

2026 · Jason Westin, David Elsea, et al. · Value in Health

Ee356 Cost-effectiveness of Subcutaneous Mosunetuzumab Plus Polatuzumab Vedotin Versus Rituximab Plus Gemcitabine and Oxaliplatin for United States (us) Patients With Autologous Stem Cell Transplant-ineligible Relapsed/refractory Large B-cell Lymphoma

2026 · Jason Westin, Kate Rosettie, et al. · Value in Health

Co147 Novel Therapies for Relapsed/refractory Mantle Cell Lymphoma Post Bruton’s Tyrosine Kinase Inhibitor: a Targeted Literature Review

2026 · Nissen Weisman, Andrea Lo-Rossi, et al. · Value in Health

Patient preferences regarding bispecific antibody (BsAb) treatment schedules and clinical profiles in second-line or later (2L+) diffuse large B-cell lymphoma (DLBCL).

2026 · Zachary Frosch, Anthony Masaquel, et al. · Journal of Clinical Oncology

Works count: 7

Citation count: 13

H-index: 1

I10-index: 1